Pyrophosphoric Acid

Pyrophosphoric Acid

SCHEMBL728738

O=P(O)(O)OP(=O)(O)O.[KH].[KH].[NaH].[NaH]

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.83
BLM P54132 1/20 0.83
TDP1 Q9NUW8 1/20 0.83
CA4 P22748 1/20 0.35
INPPL1 O15357 2/20 0.33
INPP5A Q14642 2/20 0.33
BTN3A1 O00481 2/20 0.33
SMPD1 P17405 1/20 0.33
INPP5B P32019 1/20 0.33
CA2 P00918 1/20 0.33
ITPR3 Q14573 3/20 0.32
ITPR2 Q14571 1/20 0.32
ITPR1 Q14643 1/20 0.32
SLC34A1 Q06495 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrophosphoric Acid SCHEMBL28173086 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL11100638 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL3906355 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL11605726 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL9746505 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL4821951 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL11097304 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL8904507 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL22656983 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL1163743 1.00 FDPS (0.83) FDPSBLMTDP1CA4INPPL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115531225-A Oral composition containing hinokitiol 株式会社LG生活健康 2022-12-30 CN claimed
JP-2011525128-A 2011-09-15 JP claimed
EP-2310459-A2 IMPROVED CROSS-LINKED COMPOSITIONS Lifebond Ltd (IL) 2011-04-20 EP claimed
WO-2009153750-A2 IMPROVED CROSS-LINKED COMPOSITIONS LIFEBOND LTD (IL) 2009-12-23 WO claimed
CN-115531225-A Oral composition containing hinokitiol 株式会社LG生活健康 2022-12-30 CN disclosed
CN-109789077-B Oral composition 狮王株式会社 2022-10-21 CN disclosed
EP-3082713-B1 ORAL CARE COMPOSITIONS AND METHODS COLGATE PALMOLIVE CO (US) 2020-02-05 EP disclosed
EP-3082712-B1 ORAL CARE COMPOSITIONS AND METHODS COLGATE PALMOLIVE CO (US) 2019-08-28 EP disclosed
US-9974730-B2 Oral care compositions and methods COLGATE-PALMOLIVE COMPANY (US) 2018-05-22 US disclosed
US-9814666-B2 Oral care compositions and methods COLGATE-PALMOLIVE COMPANY (US) 2017-11-14 US disclosed
EP-3237069-A1 ORAL CARE COMPOSITIONS Kiromic, LLC (US) 2017-11-01 EP disclosed
US-20160331670-A1 ORAL CARE COMPOSITIONS AND METHODS COLGATE PALMOLIVE CO (US) 2016-11-17 US disclosed
WO-2006068973-A2 METHODS FOR USE OF ORAL CARE COMPOSITIONS CONTAINING FREE-B-RING FLAVONOID ANTI-OXIDANTS COLGATE-PALMOLIVE COMPANY (US) 2006-06-29 WO disclosed
US-20060134015-A1 Methods for use of oral care compositions containing free-B-ring flavonoid anti-oxidants TRIVEDI HARSH M 2006-06-22 US disclosed
US-20060008423-A1 Dentifrice compositions and abrasive systems ARAYA ABRAHAM 2006-01-12 US disclosed
WO-2005027858-A2 A DENTIFRICE COMPOSITION COMPRISING A SOLUBLE CALCIUM SEQUESTERNG AGENT GLAXO GROUP LIMITED (GB) 2005-03-31 WO disclosed
EP-0887050-A2 Tartar control dental floss McNEIL-PPC, INC. (US) 1998-12-30 EP disclosed
US-4678662-A IMPROVED TASTE AND FLUORIDE ION STABILITY MONSANTO COMPANY (US) 1987-07-07 US disclosed
EP-0219483-A2 Pyrophosphate coating process for calcium carbonate dental abrasives Monsanto Company (US) 1987-04-22 EP disclosed
US-4464403-A REDUCING MAGNESIUM ACTIVITY OF COCOA BY CHELATION, PRECIPITATION OR ION EXCHANGING GENERAL FOODS CORPORATION (US) 1984-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060134015-A1 Methods for use of oral care compositions containing free-B-ring flavonoid anti-oxidants LPO, CAT, PROC FDPS 2153/4885BLM 1664/4885TDP1 2202/4885
US-20160331670-A1 ORAL CARE COMPOSITIONS AND METHODS ALG1, TAS2R39, KRTCAP2 FDPS 2453/4885BLM 2016/4885TDP1 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.